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Abstract
Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide. Sorafenib is
the only drug available that improves the overall survival of HCC patients. P-glycoprotein
(P-gp), Multidrug resistance-associated proteins 2 and 3 (MRP2 and 3) and Breast cancer
resistance protein (BCRP) are efflux pumps that play a key role in cancer chemoresistance.
Their modulation by dietary compounds may affect the intracellular accumulation and thera-
peutic efficacy of drugs that are substrates of these transporters. Genistein (GNT) is a phy-
toestrogen abundant in soybean that exerts its genomic effects through Estrogen-
Receptors and Pregnane-X-Receptor (PXR), which are involved in the regulation of the
above-mentioned transporters. We evaluated the effect of GNT on the expression and activ-
ity of P-gp, MRP2, MRP3 and BCRP in HCC-derived HepG2 cells. GNT (at 1.0 and 10 μM)
increased P-gp and MRP2 protein expression and activity, correlating well with an in-
creased resistance to sorafenib cytotoxicity as detected by the methylthiazole tetrazolium
(MTT) assay. GNT induced P-gp and MRP2 mRNA expression at 10 but not at 1.0 μM con-
centration suggesting a different pattern of regulation depending on the concentration. In-
duction of both transporters by 1.0 μMGNT was prevented by cycloheximide, suggesting
translational regulation. Downregulation of expression of the miR-379 by GNT could be as-
sociated with translational regulation of MRP2. Silencing of PXR abolished P-gp induction
by GNT (at 1.0 and 10 μM) and MRP2 induction by GNT (only at 10 μM), suggesting partial
mediation of GNT effects by PXR. Taken together, the data suggest the possibility of nutri-
ent-drug interactions leading to enhanced chemoresistance in HCC when GNT is ingested
with soy rich diets or dietary supplements.
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Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It ranks as
the fifth most frequent cancer and the third leading cause of cancer mortality worldwide [1].
The traditional management of HCC depends on the stage at which the disease is diagnosed
and consists of surgical resection, ablation or liver transplantation [2]. Conventional chemo-
therapy with agents such as 5-fluorouracil, epirubicin and doxorubicin has been applied as pal-
liative treatment but survival improvement in the majority of the patients is negligible [3].
Sorafenib (Sfb) is a small tyrosine kinase inhibitor that has been proved to be successful in
renal cell carcinoma treatment. It targets vascular endothelial growth factor receptors, Raf ki-
nase and platelet-derived growth factor receptor-b, thus inhibiting tumor proliferation and an-
giogenesis [3, 4]. A large prospective randomized controlled trial done in 2008 showed that Sfb
treatment improved overall survival in advanced stages of HCC [5]. This was further con-
firmed in a second trial done on Asian population [6].
A major mechanism by which many cancer cells develop resistance to chemotherapy is
known as multidrug resistance, a phenotype characterized by diminished intracellular drug ac-
cumulation leading to treatment failure [7]. Multidrug resistance has been correlated to overex-
pression of transporters belonging to the ATP binding cassette (ABC) superfamily like P-gp/
ABCB1, MRP2/ABCC2, MRP3/ABCC3 and BCRP/ABCG2 among other factors [7–9]. Physio-
logically they localize to the plasma membrane of several epithelial cells such as hepatocytes,
renal tubular cells and enterocytes [7–10]. P-gp transports mainly amphipathic, hydrophobic
and cationic compounds [7, 10]. Its overexpression has been associated with increased resis-
tance to doxorubicin in HCC [11, 12]. MRP2 and MRP3 transport organic anions usually con-
jugated with glutathione, sulfate or glucuronic acid [8, 9]. In a study involving HCC patients
who underwent tumor resection, increased MRP2 expression was associated with a poorer re-
sponse to neoadjuvant chemotherapy with cisplatin [13]. In other malignancies, like esophage-
al squamous cell carcinoma, MRP2 was shown to regulate the sensitivity to the treatment with
5-fluorouracil, doxorubicin and cisplatin and, moreover, its overexpression was correlated with
a poorer prognosis of the disease [7–10]. MRP3 was associated with resistance to methotrexate
[14]. BCRP transports a wide range of conjugated and unconjugated xenobiotics and was dem-
onstrated to mediate resistance to chemotherapeutic agents like daunorubicin and mitoxan-
trone [15, 16]. As far as HCC is concerned, there is evidence associating BCRP overexpression
with resistance to doxorubicin in vitro [17]. It was reported that Sfb intracellular accumulation
is modulated by P-gp, MRP2 and BCRP [18, 19] due to the extrusion of either Sfb itself or its
metabolites, which exhibit also chemical properties typical of P-gp and MRP2 substrates
[10, 20, 21]. Consequently, acquired resistance to Sfb due to an increased drug extrusion (e.g.
after transporter induction) may be expected.
The expression and activity of these transporters can be modulated by factors like diet, hor-
mones, aging, diseases or drugs [10, 22, 23]. Regulation can occur either at the transcriptional
or posttranscriptional level, resulting in changes in mRNA levels and, usually, in protein con-
tent, or at translational or posttranslational level resulting in changes in protein content and
dissociation from mRNA levels [9, 10, 22, 24]. Induction of transporter expression by xenobi-
otics is usually mediated by nuclear receptors. Pregnane X receptor (PXR, NR1I2) is a nuclear
receptor considered the main xenosensor regulating genes involved in drug disposition, includ-
ing P-gp, MRP2, MRP3 and BCRP [9, 22, 25]. Recently, it was demonstrated that miRNAs are
additional factors involved in modulating transporter expression. For instance, miR-223 and
miR-379 were shown to affect the expression of P-gp and MRP2, respectively [12, 26].
Genistein (GNT), a phytoestrogen that belongs to the family of isoflavones, is ingested as a
component of vegetables (e.g. soy beans, fava beans, lupins) or as a dietary supplement
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[27, 28]. GNT is considered to exert antioxidant and anticarcinogenic effects [29, 30]. However,
it is controversial whether these beneficial properties are achieved at plasma concentrations
compatible with GNT ingestion as part of a soy rich diet or GNT containing supplements,
which range between 0.5 and 10 μM [30, 31, 32]. Up to date there is little information on GNT
potential to act as modulator of the expression and activity of ABC transporters in HCC. If so,
a reduced intracellular accumulation of chemotherapeutic agents, substrates of these transport-
ers, would be expected. This fact may account for a reduced therapeutic efficacy. The aim of
this work was to evaluate the effect of GNT on the expression and activity of P-gp, MRP2,
MRP3 and BCRP in the human HepG2 cell line, derived from HCC, and the underlying molec-
ular mechanisms. Additionally, whether the observed changes in transporter activities modify
the Sfb cytotoxic effect was also assessed.
Materials and Methods
Chemicals
1-chloro-2,4-dinitrobenzene (CDNB), cycloheximide, dinitrophenyl-S-glutathione (DNP-SG),
genistein (GNT), MK571, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltretazolium bromide
(methylthiazole tetrazolium, MTT), perchloric acid, phenylmethylsulfonyl fluoride and leu-
peptin were from Sigma-Aldrich (St. Louis, MO, USA). PSC833 and calcein-AM were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Sorafenib (Sfb) was from Cayman Chemi-
cals (Ann Arbor, MI, USA). DMSO was purchased fromMerck (Darmstadt, HE, Germany).
All other chemicals were of analytical grade purity.
Cell culture and treatments
As reported for HCC [33, 34], HepG2 cells present reduced expression of ERα and absence of
ERβ [35]. Nevertheless, they retain cell polarity, this being essential for proper localization of
membrane transporters [36]. HepG2 cells also conserve the expression of PXR [37].
HepG2 cells were obtained from the American Tissue Culture Collection (Rockville, MD,
USA). Cells were grown in Dulbecco's modified Eagle's medium (DMEM) and Ham's F-12 me-
dium (Invitrogen, Carlsbad, CA, USA) at a 1:1 proportion, supplemented with 10% FBS (PAA,
Pasching, Austria), 2 mM L-glutamine, a mixture of antibiotics (5 mg/ml penicillin, 5 mg/ml
streptomycin and 10 mg/ml neomycin) and 0.1 mg% insulin (Invitrogen). Cells were incubated
at 37°C in a humidified atmosphere containing 5% CO2 as described [35]. For the treatments,
unless otherwise stated, cells were seeded in 6-well plates at a density of 3.5x105 cells/well and
cultured for 24 h. Following, GNT was dissolved in DMSO and added to treatment medium at
different concentrations (0.1, 1.0 or 10 μM) within the range reported in plasma for individuals
consuming a soy-rich diet or GNT containing supplements [31, 32]. Only DMSO was added to
control cells (C). The final concentration of DMSO in the culture media was always below 0.1%.
Cells were cultured in the presence of GNT or DMSO for 48 h. Treatment medium consisted of
the growth medium described above with FBS being replaced by Charcoal-dextran stripped FBS
(Hyclone, Logan, UT, USA), which provides a lower level of steroid hormones than standard
FBS [35]. All treatments were performed in phenol red-free culture medium. To assess whether
the effect of GNT (1.0 μM) treatment on P-gp andMRP2 occurs at the translational level, cells
were coincubated with cycloheximide (100 μM) as a protein synthesis inhibitor [38].
Western blot and real time RT-PCR studies
The effect of GNT on P-gp, MRP2, MRP3 and BCRP protein expression was initially assessed
in cell lysates. HepG2 cells were washed twice with cold PBS and scraped with RIPA buffer
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(Thermo Scientific, Rockford, IL, USA) supplemented with phenylmethylsulfonyl fluoride
(17 μg/ml) and leupeptin (15 μg/μl) as protease inhibitors. Lysates were passed 20 times
through a 25G needle and subjected to protein concentration assessment [37].
To evaluate more specifically the expression of P-gp and MRP2 at the cell surface, plasma
membranes from HepG2 cells were isolated as described by Kubitz et al. [39]. Briefly, the cells
were scraped in a buffer containing Tris 20 mM, sucrose 250 mM, EGTA 5 mM and MgCl2
1 mM supplemented with protease inhibitors. Cell lysis was achieved passing the cell suspen-
sion 20 times through a 25G needle. Plasma membranes were obtained after centrifugation
(5 min, 1000 g, 4°C). Protein concentration was quantified by the Lowry method [37].
Western blotting and bands quantification were performed as previously described [35].
Primary antibodies were: anti-BCRP, BXP-21; anti-GAPDH, FL-335; anti-P-gp, H-241 (Santa
Cruz Biotechnology); anti-MRP2, M2III-6 (Enzo Life Sciences, Farmingdale, NY, USA); anti-
MRP3, M3II-21 and anti-β-actin, A-2228 (Sigma-Aldrich). HRP-conjugated goat anti-Mouse
IgG (H+L) (Thermo Scientific) was used as secondary antibody for BCRP, MRP2 and β-actin
detection, whereas a HRP-conjugated donkey anti-Rabbit IgG (H+L) (Thermo Scientific) was
used as secondary antibody for GAPDH, P-gp and MRP3 detection.
Real time RT-PCR was performed only if changes in protein expression were detected by
western blotting. Total RNA was isolated using TRIzol reagent (Invitrogen). cDNA was synthe-
sized from 1 μg of total RNA with the Superscript III Reverse Transcriptase (Invitrogen) using
random hexamers according to manufacturer's instructions. Real time PCR reactions were car-
ried out on a MX3000P system (Agilent Technologies, Santa Clara, CA, USA) with Platinum
Taq DNA Polymerase (Invitrogen). The amount of template was quantified with SYBR Green
(Invitrogen). Primers were used at a final concentration of 1 μM. Primer sequences were:
MDR1(F): 5'CCAAAGACAACAGCTGAAA3'; MDR1(R): 5'TACTTGGTGGCACATAAAC3';
MRP2(F): 5'AGGTTTGCCAGTTATCCGTG3'; MRP2(R): 5'AACAAAGCCAA-
CAGTGTCCC3'; 18S(F): 5'CGCCGCTAGAGGTGAAATTC3'; 18(R):
5'TTGGCAAATGCTTTCGCT3' [40]. The thermocycling regime was 95°C for 2 min followed
by 40 cycles of 95°C for 15 sec, 55°C for 30 sec and 72°C for 30 sec. Relative levels of MDR1
(encoding P-gp) and MRP2 mRNA normalized to 18S rRNA were calculated based on the
2-ΔΔCt method [35]. Specificity of each reaction was verified by the dissociation curve between
55°C and 95°C.
Assessment of transport activities
Activity measurements were performed in those GNT groups exhibiting increases in transport-
er expression. The activity of P-gp was assessed measuring intracellular retention of fluorescent
calcein, which inversely correlates with transporter activity [41]. Cells were cultured in 6-well
plates as previously described, trypsinized, resuspended, and incubated (15 min, 37°C) in
500 μL of growth medium containing 0.5 μM of calcein-AM. They were then washed and re-
suspended in cold PBS. Intracellular fluorescence was quantified in a Cell Sorter BD FACSAria
II device (BD Biosciences, San Jose, CA, USA) using a blue laser (488 nm, 20 mW) and FITC
detection filter (530/30 nm). Measurements were restricted to live cells by gating them accord-
ing to the typical forward and side scatter pattern of live cells. P-gp participation was confirmed
using the specific inhibitor PSC833 (10 μM) [41].
The activity of MRP2 was quantified as previously reported through determination of the
amount of the model substrate dinitrophenyl-S-glutathione (DNP-SG) extruded into the incu-
bation medium [40]. Briefly, cells were cultured in 6-well plates and treated with GNT (1.0 or
10 μM, 48 h) as described above. Then, treatment medium was replaced with fresh medium
containing CDNB (0.5 mM) and cells were incubated at 10°C for 30 min to allow CDNB to
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passively diffuse into the cytosol. In this condition, CDNB conversion to DNP-SG occurs spon-
taneously, i.e independently of GST activity [40]. At the end of incubation the medium was
rinsed and cells were promptly washed twice with cold PBS. To evaluate the rate of DNP-SG se-
cretion, cells were incubated with HBSS buffer at 37°C for 60 min. At the end of incubations,
aliquots were subjected to centrifugation (3 min, 300 g, 4°C), supernatants were treated with
10% perchloric acid, centrifuged (2 min, 14000 g, 4°C) and the supernatants used for DNP-SG
detection by HPLC using a Waters 600 device (Waters, Milford, MA, USA) as described [40].
MRP2 participation was confirmed using MRPs inhibitor MK571 (10 μM) [42].
Cytotoxicity assays
To further assess the functional consequences of transporter induction we studied the protec-
tive role of GNT treatment against the cytotoxicity exerted by sorafenib (Sfb), substrate of P-
gp, MRP2 and BCRP [4, 18, 19]. For this purpose HepG2 cells were seeded in 96-well plates
(1.5x104 cells/well). After 24 h of culture, fresh medium containing 1.0 or 10 μMGNT was
added and cells were further incubated for 48 h. Cells were then rinsed and incubated with dif-
ferent concentrations of Sfb (0–200 μM) for 16 h. P-gp and MRP2 participation was confirmed
coincubating the cells either with 10 μM PSC833 (P-gp inhibitor), with 10 μMMK571 (MRP2
inhibitor) or with PSC833 and MK571 (10 μM each). CYP3A4 participation in the modulation
of Sfb cytotoxicity was assessed coincubating the cells with 1.0 μM ketoconazole (CYP3A4 in-
hibitor) [43]. Cell viability was then evaluated through the MTT assay as described [37].
MicroRNA quantification
Total RNA was isolated with TRIzol (Invitrogen) as described above from control and 1.0 μM
GNT treated cells, and the expression of mature miR-223, miR-379 and miR-451 was quanti-
fied through Stem Loop RT-PCR followed by quantitative PCR [44]. Stem Loop RT-PCR was
performed using 1 μg of total RNA. Stem Loop (SL) oligonucleotides and housekeeping (5S
rRNA for miR-223 and U6 snRNA for miR-379 and miR-451) specific primers were used at
50 nM and 750 nM, respectively. Retrotranscription was performed using SuperScript III Re-
verse Transcriptase (Invitrogen) with specific primers according to manufacturer's instruc-
tions. The thermal profile consisted of a first incubation for 30 min at 16°C, followed by 30 min
at 42°C, 60 min at 50°C and finally 15 min at 70°C. Primer sequences were: miR-223 SL:
5'GTCTCCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGGAGACTGGGGT3' (miR-
Base accession MIMAT0000280), miR-379 SL: 5'GTCTCCTCTGGTGCAGGGTCCGAGG-
TATTCGCACCAGAGGAGACCCTACG3' (miRBase accession MIMAT0000733); miR-451
SL: 5' GTCTCCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAGGAGACAACTCA3'
(miRBase accession MIMAT0001631); U6 snRNA: 5'CCAGTGCAGGGTCCGAGGT3'; 5S
rRNA: 5'GCGGTCTCCCATCCAAGTAC3'. All stem loop primers were designed to amplify
only the specified mature miRNAs yielding a cDNA with the necessary length to be detected in
the following real time PCR assays [44].
Real time PCR reactions for microRNA quantification were carried out on a MX3000P sys-
tem (Agilent Technologies) with Platinum Taq DNA Polymerase and SYBR Green quantifica-
tion (Invitrogen). Primers were used at a final concentration of 1 μM. cDNA samples were
used at 1/50 dilution for miR-223 and 1/10 dilution for miR-379 and miR-451. Primer se-
quences were: miR-223 (F): 5'GCAGCCTGTCAGTTTGTCA3'; miR-379(F):
5'CGGCCTGGTAGACTATGGA3'; miR-451(F): 5'GCTCGGAAACCGTTACCATTA3'; uni-
versal reverse primer: 5'GAGGTATTCGCACCAGAGGA3'; U6 snRNA(F):
5'TGCGGGTGCTCGCTTCGGCAGC3'; U6 snRNA (R): 5'CCAGTGCAGGGTCCGAGGT3';
5S rRNA (F): 5'TACGGCCATACCACCCTGAA3' and 5S rRNA (R):
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5'GCGGTCTCCCATCCAAGTAC3'. The thermocycling regime was 95°C for 1 min followed
by 40 cycles of 95°C for 15 sec, 54°C (for miR-223) or 60°C (for miR-379 or miR-451) for
30 sec and 72°C for 40 sec. Relative levels of miR-223 normalized to 5S rRNA and miR-379 or
miR-451 normalized to U6 snRNA in control and GNT 1.0 μM treated cells were calculated
based on the 2-ΔΔCt method [35]. Specificity of each reaction was verified by the dissociation
curve between 55°C and 95°C.
Knock down of PXR
HepG2 cells (5x104 cells/well) were seeded in 24-well plates, incubated at 37°C and subjected
to transfection 24 h later. Human PXR was transiently knocked down with 100 nM of PXR
siRNA (h) (Santa Cruz Biotechnology, sc-44057) targeting the human PXR mRNA (PXR-
cells). Control siRNA-A (Santa Cruz Biotechnology, sc-37007), a non-targeting siRNA, was
used as control (PXR+ cells). Transfections were performed using Dharmafect4 Transfection
Reagent (Dharmacon, Lafayette, CO, USA) as described [37]. Twenty four h after initiation of
transfection, GNT (at 1.0 or 10 μM final concentration) was added to the transfection medium.
Twenty four h later, the medium containing siRNA (or control siRNA-A) was removed, fresh
treatment medium containing GNT (or vehicle) was added, and cells were further incubated
for 24 h. At the end of the incubation, they were rinsed, scraped and used in western blot stud-
ies as described above.
Statistical analysis
Data are presented as mean ± S.D. Statistical analysis was performed using the Student t test
(for two experimental groups) or One-Way ANOVA followed by Newman-Keuls post hoc test
(for more than two experimental groups). Significance was set at p< 0.05. Studies were per-
formed using the GraphPad Prism 3.0 software (GraphPad Software, La Jolla, CA, USA).
In the case of cytotoxicity studies, cell viability measures (% of viable cells) were plotted as a
function of the decimal logarithm of Sfb concentration. The curves were best adjusted to a sig-
moid curve using the GraphPad Prism 3.0 software (GraphPad Software, La Jolla, CA, USA).
The goodness of adjustments was confirmed with R2 values, which were always above 0.85.
Results
Effect of GNT on protein expression and activity of drug transporters
GNT increased protein levels of P-gp and MRP2 at 1.0 μM (+206% and +102%, respectively)
and at 10 μM (+402% and +390%, respectively) in cell lysates, with no changes at 0.1 μM con-
centration, clearly showing a concentration-dependent response (see Fig. 1A and 1B). In con-
trast, GNT did not affect protein levels of MRP3 (Fig. 1C) or BCRP (Fig. 1D) at any of the
concentrations tested.
To determine the functional impact of P-gp and MRP2 upregulation by GNT, we evaluated
their transport activities using two different experimental strategies that were found to be opti-
mal in each case. Intracellular accumulation of calcein was lower in GNT treated cells than in
control cells (-37% and -43%, for GNT 1.0 and 10 μM, respectively) (Fig. 2). Intracellular con-
tent of calcein was increased by the P-gp specific inhibitor PSC833 in both control and GNT
treated cells, confirming the contribution of P-gp to calcein efflux. Also, we observed a higher
excretion rate of DNP-SG in 1.0 and 10 μMGNT treated cells (23% and 26%, respectively)
(Fig. 3). The addition of MK571 inhibited the efflux of DNP-SG both in control and GNT
treated cells, consistent with participation of a MRP transporter.
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Despite the higher P-gp and MRP2 protein expression in lysates from cells incubated with
10 μM of GNT than from those incubated with the 1.0 μM concentration (Fig. 1A and B), the
enhancements of transport activities were of similar extent between the two concentrations
(Figs. 2 and 3). In an attempt to elucidate the reasons for such discrepancy, we evaluated the ef-
fect of GNT (1.0 and 10 μM, 48 h) on P-gp and MRP2 protein expression in crude plasma
membranes, since the correct localization of these proteins is essential for their proper func-
tion, among other factors [45]. MRP2 protein expression did not exhibit a significant difference
between 1 and 10 μM (Fig. 4). Thus, this could be the reason for the unchanged DNP-SG excre-
tion between 1 and 10 μM. However, this may not be the case for P-gp since there is a slight
but significant increase in P-gp protein expression in plasma membrane at 10 μM compared
Fig 1. Effect of GNT on transporter expression in cell lysates. Expression of P-gp (panel A), MRP2 (panel B), MRP3 (panel C) and BCRP (panel D) was
quantified by western blotting in HepG2 lysates after 48 h of treatment with GNT (0.1, 1.0, or 10 μM) or vehicle (C). Fifteen μg of total protein were loaded in
the gels. Transporter O.D. were normalized to β-actin O.D. Uniformity of loading and transfer from gel to PVDFmembrane was also controlled through
Ponceau S staining. The data (mean ± S.D., n = 3) are expressed as percentage of the normalized transporter expression in control (C) cells. Typical western
blot detections are shown at the bottom. a: different from control, b: different from GNT 1.0 μM. p<0.05.
doi:10.1371/journal.pone.0119502.g001
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with 1.0 μM (Fig. 4), whereas the intracellular levels of calcein were similar between both
GNT concentrations.
Impact of drug transporters induction by GNT on Sfb cytotoxicity
It was of interest to study if GNT pretreatment of HepG2 cells could affect the cytotoxicity pro-
duced by Sfb, a drug used for HCC treatment. The protective effect of GNT against Sfb cytotox-
icity was evaluated through determination of cell survival. IC50 values from control and GNT
pretreated cells are shown in Table 1. The results showed that the IC50 was higher in cells treat-
ed with GNT (1.0 and 10 μM) than in control cells. These effects were prevented by the inhibi-
tion of P-gp with PSC833, the inhibition of MRP2 by MK571 and the simultaneous inhibition
of both transporters. Thus, an association can be established between upregulation of P-gp and
MRP2 and resistance to cytotoxicity exerted by Sfb in HepG2 cells. Additionally, when P-gp
was inhibited by PSC833 the cytotoxic effect of Sfb was higher than in the presence of the
MRP2 inhibitor, MK571, suggesting a major role of P-gp in cytoprotection, in all groups.
Fig 2. Effect of GNT on P-gp activity.Calcein accumulation is directly associated to accumulation of its non
fluorescent precursor calcein-AM (P-gp substrate) and was quantified by flow cytometry in control (C) and
GNT treated cells (1.0 and 10 μM, 48 h) in the absence (- PSC) or presence (+ PSC) of the P-gp specific
inhibitor PSC833 (10 μM). Data (mean ± S.D., n = 3) are presented as fold change of the calcein
accumulation in C—PSC, considered as 1. a: different from C—PSC, b: different from GNT 1.0 μM—PSC; c:
different from GNT 10—PSC. p<0.05.
doi:10.1371/journal.pone.0119502.g002
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Molecular basis of drug transporters induction by GNT
To elucidate if the upregulation of P-gp and MRP2 protein expression by GNT was at tran-
scriptional level, the corresponding mRNA levels were measured after GNT cells exposure (1.0
and 10 μM, 48 h). We found an increase in the mRNA expression of P-gp and MRP2 (+158%
and +109% respectively) only at 10 μM of GNT (Fig. 5). As mRNA levels of P-gp and MRP2 re-
mained unchanged after 1.0 μMGNT treatment, we further explored if GNT affected protein
synthesis. As seen in Fig. 6, cycloheximide abolished MRP2 and P-gp induction, agreeing well
with a regulation at translational level.
We further explored if GNT affected the expression of miR-379, since this miRNA was pre-
viously shown to modulate MRP2 protein levels in HepG2 cells. We found that GNT 1.0 μM
decreased miR-379 levels (31 ± 10% vs C: 100 ± 34%, p<0.05, n = 6) providing a possible expla-
nation for the occurrence of MRP2 upregulation without changes in mRNA levels.
Regarding P-gp translational regulation, it is known that this transporter is a target of miR-
223 in HepG2 cells [12] and that miR-223 is downregulated by GNT in pancreatic cancer cells
[46]. We evaluated the effect of GNT (1.0 μM, 48 h) on miR-223 as a potential mediator of
P-gp induction and found that its levels were not affected (76 ± 39% for GNT and 100 ± 35%
for C, p>0.05, n = 6).
Fig 3. Effect of GNT on MRP2 activity. Extrusion of the MRP2model substrate DNP-SG was quantified in
supernatants of control (C) and GNT treated cells (1.0 and 10 μM, 48 h) in the absence (- MK) or presence (+
MK) of the MRP inhibitor MK571 (10 μM). Data (mean ± S.D., n = 3) are presented as fold change of the DNP-
SG extrusion in C—MK, considered as 1. a: different from C—MK; b: different from GNT 1.0 μM—MK; c:
different from GNT 10 μM—MK. p<0.05.
doi:10.1371/journal.pone.0119502.g003
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Fig 4. Effect of GNT on transporter expression in crude plasmamembranes. Expression of P-gp (panel
A) and MRP2 (panel B) was quantified by western blotting in HepG2 crude plasmamembranes after 48 h of
treatment with GNT (0.1, 1.0, or 10 μM) or vehicle (C). Fifteen μg of crude plasmamembrane protein were
loaded in the gels. Transporter O.D. were normalized to β-actin O.D. Uniformity of loading and transfer from
gel to PVDFmembrane was also controlled through Ponceau S staining. The data (mean ± S.D., n = 3) are
expressed as percentage of the normalized transporter expression in control (C) cells. Typical western blot
detections are shown at the bottom. a: different from control, b: different from GNT 1.0 μM. p<0.05.
doi:10.1371/journal.pone.0119502.g004
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Involvement of PXR in P-gp and MRP2 induction by GNT
PXR is a nuclear receptor involved in the regulation of drug disposition by xenobiotics. It was
reported that GNT is capable of activating PXR [47]. Thus, it was of interest to evaluate if the
effects of GNT on P-gp and MRP2 were mediated by PXR. We used a siRNA driven mecha-
nism to knock down its expression as previously described and evaluated P-gp and MRP2 pro-
tein expression after incubation of these cells with GNT (1.0 and 10 μM, 48 h). The knock
down procedure results in decreasing PXR expression by 74%, according to our previous report
[37]. As expected, GNT (1.0 μM) increased P-gp and MRP2 expression by 161% and 219% in
PXR+ (Fig. 7A and B, respectively). The same figures show that GNT induction was completely
abolished in PXR- cells for P-gp but not for MRP2. Regarding treatment with GNT at the 10
μM concentration, PXR+ cells exhibited increases in protein levels by 543% and 304% for P-gp
and MRP2, respectively, consistent with findings in wild-type cells (Fig. 1A and B). Silencing of
PXR abolished the induction observed for both transporters.
Discussion
Hepatocellular carcinoma (HCC) is a high mortality malignancy that represents the fifth lead-
ing cancer by incidence worldwide. Chemotherapy is applied when surgical resection, ablation
or liver transplantation are not possible and aims to retard the progression of the disease im-
proving life quality and the overall survival of the patients [3]. Multidrug resistance is a com-
mon reason of chemotherapy failure. It is characterized by the increase in the expression of one
or more ABC transporters such as P-gp, MRP2, MRP3 and BCRP after treatment with their
substrates, leading to poorer cytotoxic and/or cytostatic effects [7, 8]. Coadministered drugs or
dietary compounds are additional factors that can enhance multidrug resistance by inducing
the expression of these transporters [10, 22, 23].
GNT is a phytoestrogen abundant in soy beans. During the last decades it was proposed
that GNT ingestion may result in cytoprotection and reduced incidence of specific tumors.
GNT beneficial effects may be attributed to its antioxidant properties as activator of the nuclear
factor erythroid 2-related factor 2 (Nrf2), to modulation of steroid hormones synthesis, or to
activation of signal transduction mechanisms that counterbalance those triggered by endoge-
nous estrogens [27, 48]. In vitro evidence suggests an antiproliferative effect of GNT in differ-
ent cell lines, including HCC models. However, these results were obtained in most of the cases
Table 1. Effect of GNT on sorafenib-induced cytotoxicity.
Sfb IC50 (μM)
Control GNT 1.0 μM GNT 10 μM
Without inhibitor 34.8 ± 3.3 46.0 ± 6.9* 43.3 ± 2.8*
PSC833 6.7 ± 2.5a 6.0 ± 1.1a 8.5 ± 4.3a
MK571 18.3 ± 6.0a,b 25.1 ± 6.3a, b 17.1 ± 1.1a, b
PSC833 + MK571 10.9 ± 4.2a,c 8.5 ± 1.7 a,c 8.0 ± 1.2a,c
IC50 values (mean ± S.D., n = 4) were obtained through nonlinear regression.
* different from control (C), p<0.05.
IC50 values were also compared within each column.
a: different from without inhibitor;
b: different from PSC833;
c: different from MK571, p<0.05.
doi:10.1371/journal.pone.0119502.t001
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using concentrations above those achieved in the plasma of individuals consuming soy rich
diets or supplements containing GNT [27, 30–32]. Additionally, it is uncertain whether GNT
affects the efficacy of chemotherapy of HCC. We recently demonstrated that GNT increases
the expression of MRP2 and P-gp in human colonic Caco-2 cells, and consequently, reduces
Fig 5. Effect of GNT on transporter mRNA expression. P-gp (panel A) and MRP2 (panel B) mRNA levels
were measured by real time RT-PCR using total RNA isolated from HepG2 cells after 48 h of treatment with
GNT (0.1, 1.0, or 10 μM) or vehicle (C). Expression of the target genes was normalized to 18S rRNA
expression. The data (mean ± S.D., n = 4) are expressed as percentage of the normalized transporter
expression in control (C) cells. *: different from all the other groups, p<0.05.
doi:10.1371/journal.pone.0119502.g005
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the intracellular accumulation of their substrates [49]. Whether GNT induces ABC transport-
ers in cell models resembling HCC, with potential to affect the efficacy of chemotherapy, is un-
known. In this work, we investigated the effect of GNT on chemoresistance in a HCCmodel.
We found that GNT, at concentrations reached in plasma of individuals with a high intake of
soy or enriched supplements (1.0–10 μM) [31, 32], increased protein expression of P-gp and
MRP2 in whole cell lysates in a concentration-dependent manner. Transport activity studies in
the presence or absence of specific inhibitors demonstrated that protein synthesis induction
was accompanied by increased capability for extrusion of their model substrates. However, no
significant differences were seen between activities detected for treatments with GNT at the 1.0
or 10 μM doses. A possible explanation is that newly synthetized P-gp or MRP2 may not be
properly localized to the plasma membrane, at least partially. Western blotting of crude plasma
membrane showed indeed no substantial difference in MRP2 expression between GNT 1.0 and
10 μM. Conversely, a slight but still significant difference was seen for P-gp expression between
both GNT concentrations in the crude membrane preparations, and in consequence other, un-
known factors, may explain expression-activity dissociation between GNT 1.0 and 10 μM.
Fig 6. Effect of cycloheximide on transporter induction by GNT. Expression of P-gp (panel A) and MRP2 (panel B) was quantified by western blotting in
HepG2 cell lysates after treatment with GNT (1.0 μM, 48 h) or vehicle (C) in the presence of the translation inhibitor cycloheximide (100 μM). Fifteen μg of
total protein were loaded in the gels. Transporter O.D. were normalized to β-actin O.D. Uniformity of loading and transfer from gel to PVDFmembrane was
also controlled through Ponceau S staining. The data (mean ± S.D., n = 3) are expressed as percentage of the normalized transporter expression in control
(C) cells. Typical western blot detections are shown at the bottom.
doi:10.1371/journal.pone.0119502.g006
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These factors could be associated with posttranslational processing of the protein such as gly-
cosylation, phosphorylation, etc., which are known to affect transport activity [10]. These pos-
sibilities were not currently explored. Taken together the data suggest that the lowest
concentration able to induced protein expression, that is 1.0 μM of GNT, led to maximal trans-
port activity and that a 10-fold increment in concentration no further increased such activity.
There is evidence associating increased P-gp or MRP2 activity with reduced accumulation
of chemotherapeutic agents and, consequently, with increased chemoresistance in cancer cells.
For instance, Manov et al. [50] reported an induction of P-gp by acetaminophen in HepG2
cells with a concomitant reduction of the accumulation and increased resistance to doxorubi-
cin. An in vivo study using a HCC xenograft model also associated P-gp activity with chemore-
sistance [51]. Regarding the role of MRP2 in HCC chemoresistance, a modulation of its
expression was correlated with resistance to vincristine both in vitro and in a xenograft model
[52]. Based on the current study, we postulate that chemoresistance may be also modulated by
GNT.
We further evaluated whether pretreatment with GNT interferes the action of sorafenib
(Sfb), the only drug demonstrated to improve overall survival of HCC patients. Our results
showed an increase in IC50 in GNT pretreated cells either at 1.0 or 10 μM, clearly suggesting
decreased Sfb efficacy. The use of selective inhibitors of P-gp and MRP2 (PSC833 and MK571,
respectively) confirmed participation of both transporters in chemoresistance. PSC833 also in-
hibits CYP3A4, which in turn metabolizes Sfb [20, 21, 53]. However, coincubation of Sfb with
Fig 7. Effect of PXR knock down on transporter induction by GNT. Expression of P-gp (panel A) and MRP2 (panel B) was quantified by western blotting
in cell lysates from control siRNA-A and PXR siRNA (h) transfected HepG2 cells (PXR+ and PXR- cells, respectively) after 48 h of treatment with GNT (0.1,
1.0, or 10 μM) or vehicle (C). Fifteen μg of total protein were loaded in the gels. Transporter O.D. were normalized to GAPDHO.D. Uniformity of loading and
transfer from gel to PVDFmembrane was also controlled through Ponceau S staining. The data (mean ± S.D. n = 3) are expressed as percentage of the
normalized transporter expression in control (C) cells. Typical western blot detections are shown at the bottom. a: different from control, b: different from GNT
1.0 μM. p<0.05.
doi:10.1371/journal.pone.0119502.g007
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ketoconazole (CYP3A4 but not P-gp inhibitor) failed to modify chemoresistance mediated by
GNT (S1 Table), ruling out a CYP3A4 role in GNT-mediated protection. PSC833 or MK571,
when used separately to inhibit either P-gp or MRP2, prevented completely the effect of GNT
on Sfb cytotoxicity, as detected in MTT assays. It is known that Sfb undergoes phase I and
phase II metabolism leading to the formation of several metabolites which are P-gp or MRP2
substrates and account for Sfb cytotoxicity [20, 21]. Transporter inhibitors also affect Sfb me-
tabolism [53] and, in consequence, the intracellular proportion of the different metabolites is
expected to change for each inhibition condition. We speculate that decreased formation of
specific metabolites, substrates of the non inhibited transporter, would result in no apparent
change in Sfb cytotoxicity due to the induction of this particular transporter.
A P-gp and MRP2 induction by GNT was also observed in Huh7 cell line, which represents
another model of HCC [54] (S1 Fig.). This induction was also associated with a protection
from Sfb cytotoxicity (S2 Table) showing that the current findings are not restricted to a partic-
ular cell line.
The molecular mechanism underlying P-gp and MRP2 induction at the protein level by
GNT was first assessed quantifying the mRNA levels of both transporters. For both genes, it
was observed an increase in mRNA levels only at the 10 μM concentration, whereas no changes
were observed at 1.0 μM, clearly suggesting that different mechanisms are involved. Cyclohexi-
mide experiments confirmed that protein synthesis is increased at the 1.0 μM concentration
suggesting translational regulation. MicroRNAs have been shown to be important in the mod-
ulation of drug transporters. They bind to the mature mRNA inhibiting translation or, alterna-
tively, increasing degradation [44]. P-gp is a known target of miR-223, which in turn was
shown to be downregulated by GNT, providing a potential explanation for mediation of P-gp
upregulation by GNT [12, 46]. We found no changes in miR-223 expression in response to 1.0
μMGNT treatment, which rules out its participation in our experimental conditions. miR-451,
which also modulates P-gp at translational level [55], was additionally evaluated but not de-
tected either in control or in treated cells. Alternative miRNAs, different from miR-223 and
miR-451 not currently explored, might be involved. MRP2 was demonstrated to be a target of
miR-379 in HepG2 cells [26]. We found that GNT significantly decreased its expression at the
1.0 μM concentration, suggesting a potential participation in translational regulation of MRP2.
MicroRNAs are considered novel targets that can influence clinical decision making and even-
tual therapeutic intervention, including the regulation of key cancer-related pathways such as
cell cycle control and the DNA damage response [56]. The fact that miRNA molecules are al-
ready entering the clinic as diagnostic and prognostic biomarkers guarantees future studies on
their relation to cancer development and therapy. Regulation of expression of miRNAs during
chemotherapy of cancer, eventually leading to chemoresistance, should be also a subject of in-
terest in such future studies.
PXR is a nuclear receptor that plays a key role in the regulation of P-gp and MRP2 expres-
sion by xenobiotics [22]. It is activated by a wide range of ligands, including GNT [47]. Using a
siRNA strategy we demonstrated PXR participation in the transcriptional regulation of both
P-gp and MRP2 by 10 μMGNT. It is known that activation of PXR leads to further binding to
a distal enhancer region of the P-gp gene bearing direct and everted repeats, thus activating P-
gp transcription [22, 25]. A similar mechanism can be proposed for MRP2, as its 5' regulatory
region bears an everted repeat at approximately -10kb and an imperfect direct repeat (DR4-
like) at approximately -12.5 kb (in silico study). We postulate that interaction between GNT
and PXR is a necessary event that triggers these transcriptional mechanisms. Interestingly,
PXR also mediated the induction of P-gp at the 1.0 μM concentration of GNT. While PXR me-
diated P-gp regulation at the transcriptional level is well known [22, 25], a translational regula-
tion has not been described yet. Considering that PXR canonical way of action involves the
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transcriptional regulation of a gene by direct binding to its promoter, our observations might
be explained through transcriptional regulation of expression of currently unknown factors,
which in turn could regulate translation of drug transporters. Our postulate is supported by re-
cent studies showing that specific cytosolic proteins regulate translation of transporters at ribo-
somal level [24]. Alternatively, PXR could modulate expression of miRNAs different from
those tested currently, also targeting P-gp mRNA, and thus regulating P-gp translation.
In conclusion, we demonstrated P-gp and MRP2 induction by GNT at 1.0 and 10 μM con-
centrations, at translational and transcriptional levels respectively, with concomitant increase
in their transport activities. The nuclear receptor PXR was partially involved in these regula-
tions. Importantly, the effect of GNT resulted in increased resistance to Sfb, the only drug avail-
able that improves the overall survival of HCC patients. Although extrapolations to the clinical
situation must be cautiously done, the possibility of nutrient-drug interactions leading to en-
hanced chemoresistance in patients with HCC when consuming a soy-rich diet or GNT sup-
plements needs to be considered.
Supporting Information
S1 Fig. Effect of GNT on ABC transporter expression in Huh7 cells.Huh7 cells were cul-
tured in a medium consisting of DMEM and Ham's F-12 medium (Invitrogen, Carlsbad, CA,
USA) at a 1:1 proportion, supplemented with 10% FBS (PAA, Pasching, Austria), 2 mM
L-glutamine and a mixture of antibiotics (5 mg/ml penicillin, 5 mg/ml streptomycin). Cells
were plated in 6-well plates (350000 cells/well). After 24 h of incubation, cells were exposed to
GNT (0.1, 1.0 and 10 μM) or vehicle (C) for 48 h in a treatment medium consisting of the
growth medium described above with FBS being replaced by Charcoal-dextran stripped FBS
(Hyclone, Logan, UT, USA) Expression of P-gp (panel A), MRP2 (panel B), MRP3 (panel C)
and BCRP (panel D) was quantified by western blotting in cell lysates from Huh7 cells as de-
scribed for HepG2 cells in Materials and Methods. Fifteen μg of total protein were loaded in
the gels. Transporter O.D. were normalized to β-actin O.D. Uniformity of loading and transfer
from gel to PVDF membrane was also controlled through Ponceau S staining. The data (mean
± S.D. n = 3) are expressed as percentage of the normalized transporter expression in control
(C) cells. Typical western blot detections are shown at the bottom. Results showed a significant
induction of P-gp (+60%) and MRP2 (+99%) at GNT 10 μMwithout changes in the expression
of MRP3 or BCRP, or at lower GNT concentrations.  different from all the other groups,
p<0.05.
(TIF)
S1 Table. Effect of ketoconazole coincubation on the protection of sorafenib-induced cyto-
toxicity by GNT. IC50 values (mean ± S.D., n = 4) were obtained through non linear regres-
sion. : different from control (C), p<0.05.
(XLSX)
S2 Table. Effect of GNT on Sfb mediated cytotoxicity in Huh7 cells. The effect of P-gp and
MRP2 induction by GNT 10 μM (48 h) on Sfb exerted cytotoxicity in Huh7 cells was assessed
by the MTT assay. Cells were plated in 96-well plates at a density of 3000 cells/well, cultured
for 24 h and exposed to GNT 10 μM or vehicle (C) for 48 h. Then, treatment medium was re-
moved and cells were incubated with Sfb (0–200 μM) for 16 h. Following, MTT assay was per-
formed as described in materials and methods. The use of selective inhibitors of P-gp and
MRP2 (PSC833 and MK571, respectively) confirmed participation of both transporters in che-
moresistance. IC50 values (mean ± S.D., n = 4) showed were obtained through nonlinear re-
gression as described in materials and methods.  different from control (C), a: different from
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the corresponding group without inhibitor.
(XLSX)
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